Home / Business and Economy / Moderna Hits 4-Year High Amid NIH Cancer News
Moderna Hits 4-Year High Amid NIH Cancer News
12 Oct
Summary
- Moderna shares surged 18% last week to a four-year high.
- NIH plans a public-private initiative for cancer vaccines.
- Moderna stock was added to the Nasdaq-100 index.
Moderna's stock experienced a substantial surge of 18% last week, culminating in its highest valuation in over four years. This remarkable climb was reportedly catalyzed by news of a planned public-private initiative by the National Institutes of Health focused on expediting cancer vaccine development.
Further bolstering Moderna's market position, the company's stock was officially included in the Nasdaq-100 index. This dual positive development underscores significant investor confidence and market anticipation surrounding the biotech firm's future prospects, particularly in the critical area of oncology therapeutics.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
